No Data
No Data
Intertrade Research Memo (8): The policy of prioritizing the strengthening of the financial structure remains unchanged, with the implementation of Dividends to occur after the elimination of carryforward losses.
Regarding the shareholder return strategy dividends of Intertrade <3747>, there have been no dividends since the September 2015 term. Currently, there are carryover losses from the past, and as stated earlier, efforts are focused on eliminating the negative retained earnings, with plans to implement dividends once this is converted to a positive balance. The importance of shareholder returns is strongly recognized, and as a return of profits to shareholders, the priority is to enhance the management foundation and improve the financial structure, aiming to increase corporate value, followed by the implementation of dividends.
Intertrade Research Memo (6): The equity ratio is over 70%. Further stability is expected with the early development of the Health Care business.
■ The financial situation of Intertrade <3747> 1. Financial situation The total amount of Assets for the fiscal year ending September 2024 decreased by 77 million yen compared to the end of the previous period, amounting to 1,645 million yen. The main factors were an increase in cash and deposits by 1024 million yen and 30 million yen, while receivables, accounts receivable, and contract assets decreased by 70 million yen. Details will be described later in "Cash Flow Situation" and "Management Indicators." Total liabilities amounted to 413 million yen, an increase of 20 million yen compared to the end of the previous period.
Intertrade Research Memo (5): The fiscal year ending September 2024 will see a decrease in revenue and a significant drop in profit. The main financial solutions will be a burden.
■ The performance trend of Intertrade <3747> 1. Performance for the fiscal year ending September 2024 The consolidated performance for the fiscal year ending September 2024 shows revenue of 1,849 million yen (a decrease of 8.1% from the previous year), operating profit of 80 million yen (a decrease of 59.8% from the previous year), ordinary loss of 159 million yen (compared to a profit of 1 million yen in the previous year), and a net loss attributable to the parent company's Shareholders of 97 million yen (compared to a profit of 36 million yen in the previous year), resulting in a landing below the initial plan in all items. In terms of revenue, the Business Solutions segment has increased revenue by 16.1%.
Intertrade Research Memo (4): Continuously exploring growth areas through the provision of advanced systems.
■ The strength of Intertrade Co., Ltd. (3747) lies in the fact that many small regional securities firms, which find it difficult to develop excellent systems independently, rely on and adopt the systems provided by the company. It is believed that the background of President Kazuya Nishimoto, who comes from a securities systems background, further supports the ability to provide advanced systems and enhances reliability. Additionally, in the main market, the securities systems sector employs new technologies worldwide.
Intertrade Research Memo (2): Diversifying into Health Care ETC with financial solutions as the core.
■Company Overview 1. Company Overview Intertrade <3747> develops Business Solutions and Health Care business primarily focused on Financial Solutions. In the Financial Solutions business, in addition to providing financial solution services such as stock trading systems for securities companies, private trading systems that allow trading without going through an Exchange, and Foreign Exchange (FX) systems, it also deals with commodities (Commodity ETF) like Gold, crude oil, soybeans, and Cryptos.
Intertrade Research Memo (1): The fiscal year ending September 2025 is finally entering the preparation phase for a leap forward.
■Summary Intertrade <3747> is a company that focuses on financial solutions, providing services such as stock trading systems for securities companies and Foreign Exchange (FX) systems. In addition to the "Financial Solutions Business," which accounts for about 80% of revenue, it also centers around the development and sales of IT Support and Group Management Solution Systems, and the development and sales of health foods and Cosmetics made from functional ingredients like Hanabira Take.